1 7 1 8 *Corresponding author 1 9 3 1 of rapid spread in immune naïve populations, it is anticipated that ZIKV will continue to 3 2 spread in the Americas and globally in regions where competent Aedes mosquito 3 3 vectors are found. Globally, dengue virus (DENV) is the most common mosquito-3 4 transmitted human flavivirus and is both well-established and the source of outbreaks in 3 5 areas of recent ZIKV introduction. DENV and ZIKV are closely related, resulting in 3 6 substantial antigenic overlap. Through a mechanism known as antibody-dependent 3 7 enhancement (ADE), anti-DENV antibodies can enhance the infectivity of DENV for 3 8 certain classes of immune cells, causing increased viral production that correlates with 3 9 severe disease outcomes. Similarly, ZIKV has been shown to undergo ADE in response 4 0 to antibodies generated by other flaviviruses. However, response to DENV antibodies 4 1
the Pan American Health Organization [22] . The primary mode of ZIKV transmission 1 4 1 appeared to be through mosquito vectors, although cases of perinatal and sexual 1 4 2 transmission were also reported [12, 23] . Given its recent history of rapid spread in 1 4 3 immune naïve populations, it is anticipated that ZIKV will continue to spread for the Guillain-Barré syndrome in French Polynesia [14, 25] and associations between ZIKV ZIKV introduction [15, 16] . DENV and ZIKV are very closely related resulting in with one serotype typically results in a life-long neutralizing antibody response to that 1 7 5 serotype, but yields cross-reactive, non-neutralizing antibodies against the other 1 7 6 serotypes. These cross-reactive, non-neutralizing antibodies are responsible for 1 7 7 antibody-dependent enhancement (ADE), a phenomenon where DENV particles are 1 7 8 bound (opsonized) by these antibodies, which allows the infection of antibody Fc as homologous immune ascites, enhanced ZIKV in culture. Of note, the fold-1 9 0 enhancement was greater for ZIKV compared to peak enhancement of other 1 9 1 flaviviruses tested against their heterologous immune ascites. Given the incidence of 1 9 2 co-circulating flaviviruses, the study authors alluded to the importance of testing human 1 9 3 sera for ADE potential of circulating flaviviruses. In a subsequent study, human cord 1 9 4 blood and sera of newborns and adults collected in Ibadan, Nigeria, was tested for ADE 1 9 5 of DENV-2, YF17D and WNV in P388D 1 , but the ADE potential of ZIKV was not tested 1 9 6
[37]. To our knowledge, only mouse sera and mouse cells have been used to date for in 1 9 7 vitro ZIKV ADE assays. In addition, anti-DENV immune serum has never been tested In this study, we investigated the role that pre-existing DENV immunity plays The collection of human blood samples was reviewed and approved by the Montréal. Informed written consent was obtained from all subjects. Jamaica 1, and 2 1 4 Singapore 1 sera have been previously described, from subject 8C and subject DA003, vaccination with yellow fever 17D vaccine. Travel history confirmed that the subject had 2 2 6 not travelled to regions outside North America and had no previous exposure to DENV 2 2 7 or ZIKV. Sera were heat inactivated for 30 min at 56°C prior to use. Anti-DENV HMAbs 1.6D and D11C isolated from subject Jamaica 1 and Singapore 1, respectively, were 2 2 9 11 kindly provided by J. S. Schieffelin from Tulane University and have been well-2 3 0 characterized and described previously [38] . The 1947 Ugandan isolate, ZIKV MR766, and DENV-1 strain HI-1, DENV-2 strain 2 3 4 NG-2, DENV-3 strain H-78, and DENV-4 strain H-42, were kindly provided by R. B. 13 Focus-forming assays were performed essentially as previously described [38] . LLC-2 7 5 MK2 target cells were seeded at a density of approximately 500,000 cells in each well of 2 7 6 a 12-well plate 24-48 hrs prior to infection. For titer assays, 10-fold serial dilutions of 2 7 7 virus were prepared. For neutralization assays, approximately 100 focus-forming units for 8 hr at room temperature, followed by secondary horseradish peroxidase-conjugated 2 9 0 goat anti-human IgG (H+L) (Pierce, Rockford, IL) incubated for 8 hr at room 2 9 1 temperature. Foci were visualized by the addition of 3,3-diaminobenzidine 2 9 2 tetrahydrochloride (Sigma-Aldrich, St. Louis, MO). Antibody-dependent Enhancement Assay Antibody-dependent enhancement assays were performed as previously described 2 9 6 [38, 39] . Briefly, 250 focus-forming units of ZIKV were mixed with human sera or HMAbs 2 9 7 14 and RPMI medium in a 200ul volume and incubated for 1 hr at 37°C. Mixtures were 2 9 8 added to 80,000 K562 cells in 300ul of complete RPMI medium and incubated for 3 2 9 9 days at 37°C, 5% (v/v) CO 2 . Control experiments were performed by pre-incubating 3 0 0 cells for 1 hr at 37 o C with a mouse anti-human FcRII MAb (anti-CD32) (Biolegend, San 3 0 1 Diego, CA). Cells were collected by centrifugation and total RNA was isolated using an 3 0 2
RNeasy Mini-kit (Qiagen, Valencia, CA) following the manufacturer's protocol. protein) [38, [40] [41] [42] [43] [44] [45] [46] . The role of the E protein is to facilitate virus entry by binding and identical. In a previous study, we characterized broadly neutralizing anti-DENV human 3 2 3 monoclonal antibodies (HMAbs) derived from patients that had recovered from DENV Their neutralization activities correlated with a strong inhibition of intracellular fusion, 3 2 7 rather than virus-cell binding. Additionally, we mapped epitopes of these HMAbs to the 3 2 8 highly conserved fusion loop region of the E protein. Given the high degree of similarity between the DENV E protein and the ZIKV E 3 3 0 protein, we thus tested the ability of two of these well-characterized anti-DENV HMAbs, 3 3 1 1.6D and D11C, to recognize the glycosylated ZIKV E surface protein using a conA 3 3 2 capture assay [38] . In this assay, the glycoprotein-binding lectin, conA, is used to the ZIKV E surface glycoprotein (Fig 1A, B) . In addition, we tested the ability of these 3 3 8 Since anti-DENV HMAbs 1.6D and D11C were cross-reactive against ZIKV, we 3 5 0 tested whether they could neutralize ZIKV infectivity using an immunostained focus- the concentrations tested (up to 40 ug/ml) (Fig 2) . Broadly neutralizing anti-DENV 3 5 7
HMAbs to recognize ZIKV-infected cells in an immunostained focus forming assay (Fig
HMAbs that target the E protein fusion loop bind to ZIKV antigens, but do not neutralize cells, which include macrophages, monocytes, and dendrocytes, correlates with 3 6 8 increased viremia and severe disease outcomes [47] . Antibodies that recognize DENV 3 6 9 surface proteins, but do not neutralize infectivity, can direct viral binding and infection of 3 7 0 certain FcR cells that are not normally infected. Since anti-DENV HMAbs 1.6D and 3 7 1 D11C cross-reacted with ZIKV proteins, but did not neutralize ZIKV infection, we tested 3 7 2 whether they could mediate ZIKV ADE in vitro. In Fig 3, we show that ZIKV infection of activity. Independent assays were repeated twice in triplicate. we wanted to investigate what might be considered the 'worst case scenario' with 3 8 5 regards to pre-existing immunity to DENV. We selected sera from individuals with the immune status of many individuals in regions where ZIKV is rapidly spreading. Singapore 1 serum blocked enhancement due to its strong neutralizing activity. Independent assays were repeated twice in triplicate. The present scenario of ZIKV introduction and spread in the Pacific and the Although the 10 amino acid E protein fusion loop region itself is identical between DENV 4 7 2 and ZIKV, the binding epitope for these HMAbs is likely to be much larger and include In this study, we also investigated the role of secondary anti-DENV sera that infection. We have confirmed that the in vitro mechanism of ZIKV enhancement occurs 4 8 1 through an FcRII-dependent process in human K562 cells in a manner very similar to 4 8 2 DENV. If ZIKV ADE is fundamentally similar to DENV ADE, it is highly likely that pre-4 8 3 existing anti-DENV antibodies will increase ZIKV viremia in humans and lead to more 4 8 4 severe disease in vivo. This correlation will need to be confirmed clinically. The authors would like to thank John S. Schieffelin at Tulane Univeristy for providing providing virus strains through the World Reference Center for Emerging Viruses and 5 1 7
Arboviruses. 
